Search the Newsreel

Lifecore Biomedical (NASDAQ:LFCR) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Lifecore Biomedical (NASDAQ:LFCR) reported its quarterly earnings, exceeding analyst estimates with an EPS loss of $0.19, $0.03 better than expected, and revenue of $34.17 million, surpassing the $32.02 million forecast. Despite a year-to-date revenue decline and widened net loss, the company reaffirmed its 2026 …

LFCR Stock Price and Chart — NASDAQ:LFCR

Lifecore Biomedical, Inc. (LFCR) is a pharmaceutical company specializing in hyaluronan-based products. Its stock price is currently $5.01, with a market capitalization of $189.64 million. The company's recent earnings report showed declining revenue and profit year-over-year, but management reaffirmed 2026 guidance due to cost …

Lifecore Biomedical Inc expected to post a loss of 22 cents a share - Earnings Preview

Lifecore Biomedical Inc is anticipated to report a loss of 22 cents per share, according to an earnings preview. This forecast is based on information shared through TradingView News, indicating an upcoming financial announcement for the company.

Lifecore Biomedical, Inc. reports results for the quarter ended June 30 - Earnings Summary

Lifecore Biomedical, Inc. has reported its financial results for the quarter that ended on June 30. The article, sourced from Reuters via TradingView News, provides an earnings summary for the company. Readers are encouraged to access the full report for detailed information.

Lifecore Biomedical Q2 FY26 net loss widens to $6.2 million; revenue falls 6.2% to $34.2 million

Lifecore Biomedical reported a wider GAAP net loss of $6.2 million in Q2 FY26, with revenue decreasing by 6.2% to $34.2 million. GAAP gross profit also fell, and non-GAAP adjusted EBITDA saw a slight decrease. Despite these financial challenges, the company signed six new …

Lifecore Signs Six New Programs, Including Two Commercial-Stage

Lifecore Biomedical reported Q2 2026 revenues of $34.2 million, a 6.2% decrease year-over-year, and a net loss of $6.2 million. Despite the revenue decline, the company reaffirmed its 2026 guidance for revenues of $120–$125 million and Adjusted EBITDA of $20.5–$25 million, citing strong business …

Lifecore Biomedical (NASDAQ: LFCR) Q2 revenue slips as 2026 guidance reaffirmed

Lifecore Biomedical reported a decline in Q2 2026 revenue to $34.2 million and an increased net loss of $6.2 million, despite growth in hyaluronic-acid manufacturing. The company reaffirmed its full-year 2026 guidance for revenue ($120-$125 million) and Adjusted EBITDA ($20.5-$25 million), highlighting a strong …

Lifecore Biomedical, Inc. Reaffirms Earnings Guidance for the Calendar Year 2026

Lifecore Biomedical, Inc. has reaffirmed its earnings guidance for the calendar year 2026, expecting revenue to be in the range of $120 million to $125 million. This announcement was made on August 5, 2026, coinciding with their Q2 2026 earnings call. The company specializes …

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore

Faruqi & Faruqi, LLP is investigating potential securities claims against Lifecore Biomedical, Inc. (NASDAQ: LFCR) on behalf of investors who suffered losses exceeding $75,000 between October 7, 2020, and March 19, 2024. The investigation stems from allegations that Lifecore made false or misleading statements …

Lifecore Biomedical Inc (LFCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Lifecore Biomedical Inc (LFCR), focusing on its price momentum, support and resistance levels, and various technical indicators, including moving averages. The current price momentum score is 4.32, with the stock trading between a resistance level of 5.16 …

Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026

Lifecore Biomedical, Inc. announced that it will report its financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, before the market opens. The company's senior management team will host a webcast at 8:00 a.m. Eastern Time on the …

Lifecore Sets Aug. 5 Webcast for Second-Quarter Results

Lifecore Biomedical (NASDAQ: LFCR) announced it will report its second-quarter financial results for the period ended June 30, 2026, on Wednesday, August 5, 2026, before market open. Senior management will host a webcast at 8:00 a.m. Eastern Time to discuss the results, with an …

BlackRock (LFCR holder) reports 2,010,546 Lifecore Biomedical shares in new ownership filing

BlackRock, Inc. has filed a Schedule 13G indicating a passive ownership stake in Lifecore Biomedical, Inc. (LFCR). BlackRock and its business units beneficially own 2,010,546 shares, representing 5.4% of Lifecore's common stock, with sole voting power over 1,988,535 shares and sole dispositive power over …

Lifecore Biomedical Inc (LFCR) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Lifecore Biomedical Inc (LFCR), a company within the Pharmaceuticals industry. It highlights that LFCR has a risk assessment score of 4.90, ranking 78 out of 155 in its industry, and a beta value of 1.07. The report …

Lifecore Biomedical Inc (LFCR) Financial Health: Profitability & Balance Sheet Analysis

Lifecore Biomedical Inc (LFCR) currently holds a weak financial score of 6.79 out of 10, ranking 134th in the Pharmaceuticals industry. While its operating efficiency is high, the company reported a year-over-year revenue decrease of 6.12% and a net profit decrease of 1.82% in …

Lifecore Biomedical signs three new customer deals, boosting 2028 revenue outlook.

Lifecore Biomedical has secured three new customer agreements for early- and late-stage development programs, including a regenerative medicine project and a medical device formulation. These deals are expected to significantly contribute to the company's revenue growth by 2028. The agreements underscore Lifecore's broad technical …

Regenerative Medicine and Device Programs Expand Lifecore’s Pipeline

Lifecore Biomedical (NASDAQ: LFCR) has announced three new customer agreements that will expand its pipeline in regenerative medicine and advanced medical technologies. These agreements include a late-stage regenerative medicine program and two early-stage programs focusing on formulation optimization, which are expected to contribute to …

Lifecore Biomedical Inc (LFCR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Lifecore Biomedical Inc (LFCR), listing its major individual shareholders and the proportion of shares they hold. It also breaks down shareholder types, such as hedge funds and investment advisors, and provides institutional shareholding data over several quarters, …

Lifecore Biomedical Inc (LFCR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Lifecore Biomedical Inc (LFCR)'s dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past 5 years, indicating no recent dividend payouts. The page also presents current stock data for LFCR.

LFCR|Lifecore Biomedical Inc|Price:4.330|Chg%:-0.100

This article provides a detailed financial summary for Lifecore Biomedical Inc (LFCR), including its recent stock performance, key financial statements like income, balance sheet, and cash flow. It highlights the company's latest earnings report with FY2025 revenue of $75.52M and an EPS of -$0.54, …

Lifecore Biomedical, Inc. Revenue Breakdown – NASDAQ:LFCR

Lifecore Biomedical, Inc. (NASDAQ: LFCR) generated $75.52 million USD in total revenue last year. Its top-performing segment, "Lifecore," contributed $128.87 million USD, an increase from $128.26 million USD in the prior year. The United States was the primary regional contributor, accounting for the same …

Lifecore Biomedical Inc (LFCR) Institutional Confidence

Lifecore Biomedical Inc (LFCR) has an institutional shareholding score of 7.00, placing it 50th in the Pharmaceuticals industry. Institutional investors hold 81.48% of its shares, an increase of 8.09% quarter-over-quarter. The largest institutional holder is ETHSX, with other significant holders including Wynnefield Capital, Inc. …

Lifecore Biomedical (LFCR) Proxy filing Summary

Lifecore Biomedical (LFCR) has released a summary of its proxy filing for the upcoming 2024 annual meeting, to be held virtually on November 7, 2024. Shareholders will vote on director elections, auditor ratification, and executive compensation, with the board recommending approval for all proposals. …

Lifecore Biomedical (LFCR) Q1 2026 earnings summary

Lifecore Biomedical's Q1 2026 summary highlights significant revenue growth in Q3 2025, reaching $31.1 million, driven by increased demand, new business wins, and strong manufacturing growth. The company strengthened its leadership, implemented operational efficiencies, and advanced its pipeline with 11 programs targeting launches between …

What Triggered Lifecore Biomedical's Recent Stock Plunge

Lifecore Biomedical (LFCR) shares plunged over 33% after its Q4 2025 earnings report, primarily due to delayed volume expectations from key customers and a cautious outlook on new GLP-1 agreements, despite otherwise solid results. The company, a specialized CDMO in aseptic fill-finish and hyaluronic …

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Lifecore Biomedical, Inc. (NASDAQ: LFCR) announced an inducement grant of 3,500 restricted stock units (RSUs) to a new employee. This RSU award, granted on July 13, 2026, was a material inducement for a newly hired employee to join the company and vests on the …

New Lifecore Hire Gets 3,500 Stock Units Vesting in Three Years

LFCR Q1 2026 Earnings: EPS Misses Estimates, Stock Declines - Financial Summary

Is Now An Opportune Moment To Examine Lifecore Biomedical, Inc. (NASDAQ:LFCR)?

LFCR Forecast — Price Target — Prediction for 2027

LFCR Q1 2026 Earnings: Wide EPS Miss as Losses Deepen - Consensus Beat Rate

Lifecore Biomedical Q1 Earnings Call Highlights

Lifecore Biomedical Reports Financial Results for the First